assembly
biosciences
announces
october
conference
participation
south
san
francisco
globe
newswire
assembly
biosciences
nasdaq
asmb
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
announced
participation
two
upcoming
conferences
focused
hbv
serum
biomarkers
virtual
workshop
panel
virological
immunological
gaps
need
addressed
biomarkers
needed
meet
hbv
cure
endpoints
panelist
william
delaney
phd
chief
scientific
officer
virology
date
time
monday
october
et
wainwright
hbv
virtual
presenter
john
mchutchison
ao
md
chief
executive
officer
president
date
time
tuesday
october
et
webcast
hbv
available
events
presentations
section
company
website
hbv
chronic
hepatitis
b
virus
hbv
infection
debilitating
disease
liver
afflicts
million
people
worldwide
million
people
china
estimated
world
health
organization
hbv
global
epidemic
affects
people
hepatitis
c
virus
hcv
hiv
infection
higher
morbidity
mortality
rate
hbv
leading
cause
chronic
liver
disease
need
liver
transplantation
one
million
people
worldwide
die
every
year
causes
current
standard
care
patients
chronic
hbv
infection
suppressive
treatment
medications
reduce
eliminate
virus
resulting
low
cure
rates
significant
unmet
need
new
therapies
treat
hbv
assembly
biosciences
assembly
biosciences
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
hbv
program
focused
advancing
new
class
potent
oral
core
inhibitors
potential
increase
cure
rates
chronically
infected
patients
microbiome
program
developing
novel
oral
live
microbial
biotherapeutic
candidates
assembly
fully
integrated
platform
including
robust
process
strain
identification
selection
gmp
manufacturing
expertise
targeted
delivery
lower
gastrointestinal
tract
technology
information
visit
contacts
assembly
biosciences
lauren
glaser
senior
vice
president
investor
relations
corporate
affairs
lglaser
